Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

Bortezomib, a proteasome inhibitor with efficacy in multiple myeloma, is associated with thrombocytopenia, the cause and kinetics of which are different from those of standard cytotoxic agents. We assessed the frequency, kinetics, and mechanism of thrombocytopenia following treatment with bortezomib...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lonial, Sagar, Waller, Edmund K., Richardson, Paul G., Jagannath, Sundar, Orlowski, Robert Z., Giver, Cynthia R., Jaye, David L., Francis, Dixil, Giusti, Sara, Torre, Claire, Barlogie, Bart, Berenson, James R., Singhal, Seema, Schenkein, David P., Esseltine, Dixie-Lee W., Anderson, Jessica, Xiao, Hugh, Heffner, Leonard T., Anderson, Kenneth C.
Formato: Artigo
Lenguaje:Inglês
Publicado: The American Society of Hematology 2005
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895114/
https://ncbi.nlm.nih.gov/pubmed/16099887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-03-1173
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares